App-Quantinova.ai

?2-Glycoprotein 1 Antibodies Directly Activate the Platelet IgG Receptor, Fc?RIIa, and Cause Thrombosis in FCGR2A Transgenic but Not in Wild Type Mice

Todd V Meyer - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Heparin

Role of Gas6 in Cancer-Induced Venous Thrombosis

Catherine A Lemarie - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Venous thrombosis

Hemostatic Solution

Impact of Venous Thromboembolism (VTE) Prophylaxis and Risk Stratification with the Caprini Model in Hospitalized Patients with Cancer

Hsou M Hu - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Venous thrombosis

Fondaparinux sodium

Rare Coding Single Nucleotide Variants of ADAMTS13 Are Associated with Deep Vein Thrombosis in a Next-Generation Sequencing Association Study

Giacomo Tuana - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Hemostatic Solution

Comprehensive Venous Thromboembolism Prevention Programme Incorporating Mandatory Electronic Risk Assessment Reduces the Incidence of Hospital-Associated Thrombosis: A Single Centre Experience

Gayle Porter - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Outpatient Treatment of Symptomatic Pulmonary Embolism: A Systematic Review and Meta-Analysis

Gregoire Le Gal - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Venous thrombosis

Heparin

Polo-Like Kinase 3, a Novel Regulator of Thrombosis: Positive Regulation of TxA2 Generation, Granular Secretion and Clot Retraction, but Negative Regulation of Integrin Activation

Brendan Bachman - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Epinephrine

Inhibitory Autoantibodies to Protein Disulfide Isomerase From Systemic Lupus Erythematosus Patients Are Prothrombotic

Joan T. Merrill - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Venous thrombosis

Phosphatidylserine

Kininogen Deficiency Protects From Ischemic Neurodegeneration in Mice by Reducing Thrombosis, Blood-Brain-Barrier Damage and Inflammation

Eva Gob - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Venous thrombosis

Rose bengal sodium

The Complex Transcriptional Landscape of the Human Platelet

Steven E. McKenzie - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Venous thrombosis

N/A

A Large Cluster of Micrornas At 14q32 Defines an RNA Expression Module That Accounts for Racial Differences in Protease Activated Receptor 4-Mediated Platelet Reactivity

Lukas M. Simon - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Venous thrombosis

N/A

Regional and Racial Differences in Venous Thrombosis in the United States: The Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study

Leslie A McClure - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Venous thrombosis

N/A

Psi Domain of b3 Integrin Has Endogenous Thiol Isomerase Function and Is a Potential New Target for Anti-Thrombotic Therapy

Pingguo Chen - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Bacitracin

Predicting Venous Thromboembolism Recurrence Risk in Patients with Cancer: A Validation Study

Gauruv Bose - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Venous thrombosis

Warfarin

Daunorubicin or Not During the Induction Treatment of Childhood Standard-Risk B-Cell Precursor Acute Lymphoblastic Leukemia (SR-BCP-ALL): The Randomized Fralle 2000-A Protocol

Arnaud Petit - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Allmercap

Safety and Feasibility of a Diagnostic Algorithm Combining Clinical Probability, D-Dimer and Ultrasonography in Suspected Upper Extremity Deep Vein Thrombosis: A Prospective Management Study

Marcello Di Nisio - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Venous thrombosis

N/A

Oral Rivaroxaban for the Treatment of Symptomatic Venous Thromboembolism: A Pooled Analysis of the EINSTEIN DVT and EINSTEIN PE Studies

Harry Roger Buller - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

rivaroxaban

A Randomized, Double-Blind, Placebo-Controlled, Phase-2B Study to Evaluate the Safety and Efficacy of Recombinant Human Soluble Thrombomodulin, ART-123, in Patients with Sepsis and Suspected Disseminated Intravascular Coagulation

Kazuhisa Tsuruta - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Venous thrombosis

Thrombomodulin alfa

Management and Outcomes of Major Bleeding On Dabigatran or Warfarin

Hun-Gyu Hwang - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Prothrombin complex

Trace FVIII Augments Rfviia Induced Thrombin Generation and Improves Hemostasis in Hemophilia A Patients with Inhibitors: A clinical Cohort Study

Uri Martinowitz - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Hemostatic Solution

Filters

7277 Abstracts